A CRO, or contract research organization, is a company that pharmaceutical and biotech firms hire to run some or all of their clinical research. Instead of building massive internal teams to test a new drug or medical device, companies outsource that work to CROs, which handle everything from designing a study to filing paperwork with regulators. The global CRO industry was valued at roughly $79 billion in 2024 and is projected to reach nearly $126 billion by 2030.
The Core Idea Behind a CRO
Developing a new drug is expensive, slow, and heavily regulated. A single clinical trial can require dozens of hospital sites across multiple countries, thousands of participants, years of data collection, and constant oversight to make sure everything meets government standards. Most companies, especially smaller biotech startups, don’t have the infrastructure to manage all of that in-house.
CROs exist to fill that gap. They employ specialists in statistics, regulatory law, data management, medical writing, and clinical operations. A drug company (called the “sponsor”) contracts with a CRO to handle specific pieces of a trial or, in many cases, the entire thing from start to finish. The sponsor retains ownership of the drug and the data, but the CRO does the operational heavy lifting.
Services a CRO Provides
The range of what a CRO can take on is broad. Some focus on a single specialty, while others offer end-to-end support across the entire drug development timeline. Here are the major service areas:
- Project management: Coordinating every moving part of a trial, from initial planning through execution to close-out.
- Site selection and activation: Identifying hospitals and clinics that are good candidates to run the trial, evaluating their capabilities, and handling the administrative setup to get them ready.
- Site management: Overseeing daily operations at trial locations, training staff, managing supplies, and ensuring data quality.
- Patient recruitment: Developing strategies to find and enroll enough eligible participants within the trial’s timeline. CROs increasingly use machine learning models that analyze historical enrollment data and real-world patient information to predict which sites will recruit most effectively.
- Data management: Collecting, organizing, and analyzing the data generated throughout the trial.
- Biostatistics: Running the statistical analyses that determine whether a treatment actually works and how significant the results are.
- Monitoring: Checking that the trial follows its protocol, standard operating procedures, and Good Clinical Practice guidelines at every stage.
- Pharmacovigilance: Tracking and reporting adverse events and safety signals during the trial.
- Medical writing: Preparing study protocols, informed consent forms, clinical study reports, and the summary documents needed for regulatory submissions.
- Regulatory affairs: Assembling and submitting the formal application packages that regulatory agencies require, then maintaining compliance throughout the process.
- Logistics: Managing the supply chain for investigational products, including shipping, storage, and distribution to trial sites.
Full-Service vs. Specialty CROs
Not all CROs look the same. Full-service CROs provide the complete suite of capabilities needed to run a clinical trial from beginning to end. They coordinate timelines and communication across all those service areas under one roof, which can simplify contracts, speed up startup, and reduce costs. Large full-service CROs operate globally and can manage trials spanning dozens of countries simultaneously.
Specialty CROs, on the other hand, focus on a narrow area. That might mean a specific therapeutic area like oncology or rare diseases, a single service like data management, a particular phase of development, or a specific type of product like medical devices. What you gain with a specialty CRO is deep, focused expertise and more flexibility. They tend to offer individualized solutions and can be more nimble when a study’s scope, timeline, or strategy shifts mid-trial. The tradeoff is that their capacity outside their specialty is limited, so you may need to contract with multiple vendors.
How CROs Fit Into Drug Development Phases
Clinical trials move through distinct phases, and CROs can be involved in any or all of them. In early-phase work (Phase I and II), trials are smaller, focused on safety and initial effectiveness, and require precise dose-finding expertise. A CRO running Phase I trials might manage a single specialized clinic with a few dozen healthy volunteers.
Phase III trials are the large-scale studies that determine whether a drug gets approved. These can involve thousands of patients across hundreds of sites in multiple countries. This is where the operational scale of a CRO becomes most valuable, since coordinating global logistics, regulatory filings in different jurisdictions, and consistent data collection across sites is enormously complex.
Phase IV trials happen after a drug is already on the market. These post-approval studies monitor long-term safety and effectiveness in larger, more diverse populations. CROs handle the ongoing data collection and safety reporting that regulators require.
Regulatory Standards CROs Must Follow
CROs operate under strict regulatory frameworks. In the United States, they must comply with FDA regulations covering human subject protection, informed consent, and the rules governing investigational new drug applications. Internationally, the standard is ICH Good Clinical Practice (GCP), a set of guidelines that ensure trial data is credible and that participants’ rights and safety are protected.
These aren’t optional best practices. Regulatory agencies audit CROs, and failures in compliance can delay or derail a drug’s path to approval. A core part of what you’re paying for when you hire a CRO is their expertise in navigating these requirements across different countries, each of which may have its own regulatory layer on top of international standards.
Why Companies Use CROs
The primary reasons are speed, cost, and access to expertise. Building an internal clinical operations team large enough to run a global Phase III trial requires hiring hundreds of specialized employees, many of whom you won’t need once the trial ends. Outsourcing to a CRO converts that fixed cost into a variable one.
CROs also reduce cycle times. Because they’ve run hundreds or thousands of trials, they have established relationships with trial sites, pre-built regulatory submission templates, trained monitors ready to deploy, and data systems already validated. A pharmaceutical company recognized that working with CROs delivers reduced cycle times, lower administrative costs, and quality improvements that would be difficult to replicate internally.
For small biotech companies with a single drug candidate and limited staff, a CRO may be the only realistic path to getting a trial done. But even the largest pharmaceutical companies in the world outsource significant portions of their clinical programs. The expertise required is simply too broad and too specialized for any single organization to maintain entirely on its own.
The Shift Toward Decentralized Trials
One significant change reshaping how CROs work is the rise of decentralized clinical trials, where some or all trial activities happen outside traditional hospital sites. This might mean participants use wearable devices to transmit health data, complete assessments through video calls, or receive investigational products by mail.
The number of registered decentralized trials grew from 46 in 2017 to 250 by the end of 2023, with a sharp acceleration during 2020. About 95% of decentralized trials now incorporate digital technology in some form, with more than half integrating digital health tools like remote monitoring devices. CROs are increasingly expected to manage these hybrid models, coordinating both in-person site visits and remote data collection within the same study. This adds complexity but also opens trials to participants who live far from traditional research centers, potentially improving both recruitment speed and the diversity of enrolled populations.